Unicycive Therapeutics (UNCY) Equity Average (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Equity Average data on file, last reported at $34.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 263.07% year-over-year to $34.0 million; the trailing twelve-month figure through Mar 2026 stood at $34.0 million (up 263.07% YoY), and the FY2025 full-year result was $18.8 million, up 938.87% from the prior year.
• Equity Average for Q1 2026 stood at $34.0 million, roughly flat from $33.8 million in the prior quarter.
• Across five years, Equity Average topped out at $34.0 million in Q1 2026 and bottomed at -$21.3 million in Q3 2024.
• The 5-year median for Equity Average is $2.1 million (2022), against an average of $3.2 million.
• The widest annual swing landed in 2022, when Equity Average soared 589.51%; it then sank 5345.07% in 2024.
• A 5-year view of Equity Average shows it stood at $2.1 million in 2022, then plunged by 109.01% to -$187500.0 in 2023, then tumbled by 5345.07% to -$10.2 million in 2024, then soared by 431.44% to $33.8 million in 2025, then grew by 0.33% to $34.0 million in 2026.
• The last three Equity Average figures came in at $34.0 million (Q1 2026), $33.8 million (Q4 2025), and $27.0 million (Q3 2025), per Business Quant data.

Peer Comparison